Comparative study on the safety and efficacy of liprodicaine cream and lidocaine cream in the treatment of facial freckle removal or dot matrix laser

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094240

Enrollment

Unknown

Registered

2024-12-19

Start date

2024-12-25

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial scar facial stain

Interventions

B group:Facial freckle treatment 60min

A group:Facial freckle treatment 40min

C group:Facial dot matrix treatment 60min

D group:Facial dot matrix treatment 90min

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1.>=18 years old, <65 years old, gender unlimited; 2.Plan to carry out freckle removal or dot matrix laser treatment on the left and right sides; 3.No acute or chronic pain; No sensory disturbance; 4.Volunteer to participate in this research and sign the informed consent;

Exclusion criteria

Exclusion criteria: 1.Allergic to amide local anesthetics or to any other component of the test drug; 2.Congenital or idiopathic methemoglobinemia; 3.Freckle or dot matrix laser treatment is performed only on one side of the face or on areas outside the face; 4.Cognitive dysfunction;

Design outcomes

Primary

Measure	Time frame
Incidence and severity of adverse reactions;	—

Secondary

Measure	Time frame
VAS;Effect of anesthesia;	—

Countries

China

Contacts

Public ContactXiangning qiu

The Second Xiangya Hospital, Central South University

xiangningqiu@csu.edu.cn+86 731 85292452

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026